. 2014 Dec 30;10:39–55. doi: 10.2147/COPD.S70162

Table S4.

Proportion of primary care physicians and respiratory specialists concordant with first- or second-choice GOLD 2011 global strategy treatment options by country

	USA n=200		Mexico n=101		Brazil n=101		France n=100		Germany n=100		Italy n=100		Spain n=100		UK n=100		NL n=101		Russia n=100		Japan n=101		SK n=103
	PC	RS	PC	RS	PC	RS	PC	RS	PC	RS	PC	RS	PC	RS	PC	RS	PC	RS	PC	RS	PC	RS	PC	RS
GOLD category B patient^a^,^¥
Concordant (%)	21	67	19	62	29	65	55	81	67	72	50	54	48	84	49	84	51	89	8	27	47	54	28	63
GOLD category C patient^b^,^¥
Concordant (%)	24	37	32	23	28	31	38	31	49	32	58	54	32	16	48	48	50	52	28	62	59	25	51	48
GOLD category D patient^c^,^†
Concordant (%)	24	41	63	65	56	38	74	69	68	44	68	69	53	56	72	88	72	85	49	38	62	64	57	52

Notes:

Scenario described to physician: this patient has an mMRC dyspnea scale score of 2, a GOLD airflow-limitation classification of 2, and had one exacerbation in the past year

scenario described to physician: this patient has an mMRC dyspnea scale score of 0, a GOLD airflow-limitation classification of 3, and had one hospitalized exacerbation in the past year

scenario described to physician: this patient has an mMRC dyspnea scale score of 2, a GOLD airflow-limitation classification of 3, and had two exacerbations in the past year

^¥

second-choice option of LAMA and LABA not evaluable

^†

second-choice options of LAMA and LABA or ICS and LAMA not evaluable. Triple therapy defined as LAMA + LABA/ICS fixed-dose combination in two inhaler devices.

Abbreviations: GOLD, Global initiative for chronic Obstructive Lung Disease; NL, the Netherlands; SK, South Korea; PC, primary care; RS, respiratory specialist; LAMA, long-acting muscarinic antagonist; LABA, long-acting β₂-agonist; ICS, inhaled corticosteroid; mMRC, modified Medical Research Council.